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Vibrational spectroscopy has emerged as a promising tool for non-invasive, multiplexed measurement of
blood constituents - an outstanding problem in biophotonics. Here, we propose a novel analytical
framework that enables spectroscopy-based longitudinal tracking of chemical concentration without
necessitating extensive a priori concentration information. The principal idea is to employ a concentration
space transformation acquired from the spectral information, where these estimates are used together with
the concentration profiles generated from the system kinetic model. Using blood glucose monitoring by
Raman spectroscopy as an illustrative example, we demonstrate the efficacy of the proposed approach as
compared to conventional calibrationmethods. Specifically, our approach exhibits a 35% reduction in error
over partial least squares regression when applied to a dataset acquired from human subjects undergoing
glucose tolerance tests. This method offers a new route at screening gestational diabetes and opens doors for
continuous process monitoring without sample perturbation at intermediate time points.
B
lood constituent (analyte) monitoring forms a substantial component of medical diagnostics, ranging from
critical-care to point-of-care testing. The concentration levels of these analytes are tightly controlled under
normal circumstances and thus any deviation from the well-established ranges can be immediately corre-
lated with an abnormality in body function. Formulation and advance of non-invasive, continuous measurement
strategies for such analytes - particularly glucose in diabetic patients1,2 - is highly desirable, given the significant
challenges and inconvenience associated with multiple blood withdrawals per day. Furthermore, such a mea-
surement technology would significantly aid neonatal and ICU patient monitoring as well as the screening for
pre-diabetes and gestational diabetes. Currently, the latter pathological conditions are diagnosed via functional
loading tests (e.g. the oral glucose tolerance test (OGTT)3), where the insulin action is monitored by discrete
finger-prick measurements over the duration of a few hours following an initial glucose stimulus.
To address this unmet clinical need for non-invasive, continuous measurement of blood analytes, vibrational
spectroscopy, especially infrared (IR) absorption and Raman4–6, has been proposed by researchers due to its
ability to quantify biochemical composition of the blood-tissue matrix without necessitating addition of exogen-
ous labels. Raman spectroscopy, in particular, has been exploited due to its exquisite chemical specificity eman-
ating from the characteristic frequency shifts of the photons following its interaction with thematrix molecule(s).
This provides an inherent advantage in targeted analysis of a specific bioanalyte as the congestion among the
broad overlapping features in IR absorption spectra often washes out the information of interest. To gainfully
employ spectroscopic techniques in bioanalyte concentration prediction, chemometric methods, such as partial
least squares (PLS) regression7 and support vector regression (SVR)8, are employed to develop calibrationmodels
from representative samples. The multivariate calibration models are then used in combination with the spec-
trum acquired from a prospective sample to compute the bioanalyte concentration in that sample.
Despite promising measurements of clinically relevant analytes (e.g. glucose, urea and cholesterol) in aqueous
solutions9 and whole blood samples10, the translation of spectroscopic techniques to in vivo measurements in
humans has proven to be challenging. The primary impediments for clinical translation has been attributed to
sample-to-sample variability in optical properties, such as those due to variations in skin-layer thickness and
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hydration state11, and in physiological characteristics12. In view of the
substantial inter-person variance, an alternate route in establishing
the potential of vibrational spectroscopy would be to perform time-
lapse measurements (in a continuous or semi-continuous manner)
on a single individual. Specifically, it would be beneficial if temporal
evolution of the concentration profile could be obtained solely from
spectral acquisitions without resorting to (intermediate) concentra-
tion measurements. This would allow for minimum sample per-
turbation be it in a biomedical setting or in chemical reaction
monitoring. Although the utility of such a protocol, which can func-
tionwith little or no concentration information, is indisputable, there
is currently a lack of analytic frameworks that can operate solely
based on the acquired spectroscopic and sample-specific kinetic
information.
In this article, we propose a novel analytical formulation that
enables spectroscopy-based prediction of analyte information, with-
out necessitating reference concentration information for the
development of the calibration model. The proposed framework is
hereafter referred to as the improved concentration independent
calibration (iCONIC) approach. We seek to solve this inverse con-
centration estimation problem by incorporating the kinetic model of
the system to guide the spectroscopy-based concentration estimates.
In other words, the kinetic model of the process provides a guide to
the ‘‘missing’’ concentration piece of the inverse problem of concen-
tration estimation. While the fundamental principles of the iCONIC
approach are generalizable to any spectroscopy-based quantification
study, this work focuses on the development and application of
the iCONIC framework using non-invasive glucose monitoring
as the paradigm. Here, we characterize the physiological lag between
the blood and interstitial fluid (ISF) glucose concentrations using a
two-compartment mass transfer framework, which has been employed
to model the analyte transport by us and others13–15. Inspired by indir-
ect implicit calibration ideas16, minimization of the spectral informa-
tion and the output of the kinetic model is then pursued in the
concentration domain. The spectroscopic calibration step is executed
inside the kinetic parameter estimation loop in an iterative fashion.
This considerably alleviates the rigidity associated with prior methods
that sought to determine a simultaneous solution to the kinetic model-
ing and the spectroscopic calibration components15.
Using concentration datasets obtained from a series of OGTTs in
human subjects, we demonstrate the potential of the iCONIC
approach in estimating blood glucose concentrations. We show that
the iCONIC estimates conform more closely to the measured values
in relation to the predictions computed from conventional PLS cal-
ibration that shows larger deviations. Additionally, this study also
provides quantitative insights into the subject’s physiological lag
characteristics potentially offering a new tool for the personalized
assessment of diabetes onset and progression. Collectively, these
findings open the door for a diverse range of spectroscopic monitor-
ing applications - especially in clinical practice where obtaining
intermediate concentration information is always challenging and
often impossible.
Results
Dynamic bioanalyte tracking by calibration-free approach.
Motivated by the need for a spectroscopy-based monitoring
algorithm that can work with limited or no reference concentration
inputs, we explore the powerful, yet relatively underutilized, idea of
indirect implicit calibration16,17 and report its first application to
quantitative biological spectroscopy. Spectroscopy-based inference of
concentration of system constituents belongs to the class of inverse, ill-
posed problems, in the sense that there can be multiple solutions that
are consistent with the experimental data18. Additionally, tracking the
temporal evolution of a constituent necessitates analysis of the spectral
time series often incorporating conservation equations of differential
nature and constitutive equations of algebraic nature into the
spectroscopic calibration framework. Continuous spectroscopy-
based non-invasive glucose monitoring offers a representative case
study, due to the physiological dynamics of glucose transport
between the blood and ISF compartments. Specifically, the time lag
between the two glucose levels gives rise to an inconsistency in
classical spectroscopic calibration models, as the spectroscopic
measurements primarily probe ISF glucose while blood glucose
values are used as reference inputs19. This problem is particularly
exacerbated when measurements are performed during rapid
changes in glucose levels such as immediately after a meal ingestion
(as is the case for OGTT) or insulin administration. Fig. 1
schematically illustrates the spectroscopic measurement process and
shows how the photons interact with the glucose molecules in the two
distinct compartments. We introduce here a novel route to address
this important problem – and related class of monitoring applications
– by minimizing the residual between two concentration profiles,
namely the profile computed from the kinetic model and that
obtained from transformation of the spectral information to the
concentration domain.
In the proposed iCONIC approach, calibration of the acquired
spectra is done using the concentrations calculated with iteratively
improved kinetic parameter(s) – and thus does not require the actual
measurement of the reference concentration values as detailed below.
Here, the calculated concentrations, C^, are considered to be ‘‘mea-
sured’’ variables and the residual-minimization is performed in con-
centration units. This represents a multivariate calibration
framework with ‘‘floating data’’16. Using concentration values C^
(which is a function of the kinetic parameters, k) and the recorded
calibration spectral matrix Y, one can compute the corresponding
regression matrix B using the least-squares solution to equation (1):
C^~ YBzE ð1Þ
where E denotes the noise (error) in measurements.
Figure 1 | A schematic illustration of the Raman spectroscopic
measurement process for in vivo continuous glucose monitoring.
www.nature.com/scientificreports
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Given the underdetermined nature of the system (as it has more
variables, i.e. wavelengths, than equations, i.e. number of calibration
data points), solution of the above equation implies calculation of a
suitable pseudo-inverse of Y, such that B^~YzC^ where B^ represents
the regression matrix estimate. The regression matrix estimate is
obtained using singular value decomposition (SVD), PLS or prin-
cipal component regression (PCR). The calibrated concentration
profiles C^cal is then determined by substitution in equation (1):
C^cal~ YY
zC^ ð2Þ
This formulation is employed to iteratively obtain the estimates of
the kinetic parameters, k, by minimizing the following residual:
Q~ C^{C^cal
 ~ C^{YYzC^
 ~ I{YYzð Þ C^  ð3Þ
Equation (3), notably, employs two altogether different concentra-
tion profiles: C^, the concentrations computed based on the conser-
vation equations governing the dynamic process; and C^cal, the
spectroscopy-based concentration estimate obtained from the cal-
ibration step. Evidently, both concentrations are dependent on the
current value of the kinetic parameters.
In order to reduce the impact of spectral baseline fluctuations and
improve the contribution of each component of the spectral data
during fitting, SVD of the spectral dataset Y is used to isolate the
important time-trace information. Detailed explanation of the spe-
cific SVD procedure and its ability to alleviate the pernicious effect of
baseline shifts is provided in Supplementary Notes. Reducing Y to
Y5USV* (where U is the abstract time-trace matrix of concentra-
tion information, S is the diagonal matrix containing the singular
values andV* is the abstract matrix of basis spectra), and replacing it
in equation 3, we obtain:
Q~ I{UUT
 
C^
  ð4Þ
While equation (4) represents the general framework for analysis
of any time-resolved spectral data recorded from a dynamic sys-
tem, the ensuing solution formalism is specialized for spectro-
scopy-based non-invasive monitoring of blood glucose. Here,
the modeled concentration (C^) and regression (B^) matrices are
replaced by the corresponding ISF glucose-specific vectors
(c^ISF,b^ISF). Since the acquired spectral data are representative of
the ISF glucose concentrations, this ensures consistency in the
developed calibration models. Additionally, to remove any
remaining ambiguity in the inversion problem, as well as to rule
out unphysical and implausible solutions, a secondary convex goal
is added by means of a regularization parameter l20. This ensures
that the minimization procedure converges on a robust solution in
the sense that small variations in the spectral dataset do not cause
large variations in the computed kinetic parameters, k, and the
resultant regression matrix.
Qreg~ I{UU
T
 
c^ISF
  2zl kk k2?min ð5Þ
Where c^ISF is assessed from the reverse form of the mass conser-
vation-based model that governs the blood and ISF glucose rela-
tionship, as detailed in the Methods section. The residual of
equation (5), Qreg, is minimized using the Newton-Gauss-
Levenberg/Marquardt (NGLM) algorithm21 for identification of
the optimal kinetic parameters, kopt (see Supplementary Note 1).
Solution of equation (5) yields the set of optimal ISF glucose con-
centrations (via kopt), which in turn is used to calculate the ISF
glucose-specific regression vector b^ISF. Using this regression vector
in conjunction with the spectrum measured at the prediction time
point (spred), one can predict the ISF glucose concentration:
cISF,pred~(spred)
Tb^ISF ð6Þ
The set of predicted ISF glucose concentrations can be transformed
using the forward form of the physiological glucose dynamics model
and knowledge of the kinetic parameters kopt to construct the cor-
responding blood glucose estimates.
Calculation of BloodGlucose concentration. Fig. 2 shows themean
and 61 standard deviation (SD) of representative Raman spectra
acquired from a human volunteer undergoing an OGTT. The SD
tomean ratio of the intensity values over the fingerprint region of the
spectrum, 300–1700 cm21, ranges from 0.03 to 0.1. The tissue
spectral signatures can be attributed to the presence of Raman-
active components (such as from blood analytes, collagen I and III,
structural proteins in the epidermis and dermis, and sub-cutaneous
lipids) and endogenous fluorophores. While the near-infrared (NIR)
excitation considerably reduces the autofluorescence levels, the
presence of a broad background can still be observed in the
acquired spectra. The strongest Raman peak is observed at ca.
1445 cm21 and other prominent features are located at
approximately 859, 938, 1004, 1273, 1302 and 1655 cm21, which is
consistent with prior in vivo tissue observations22. Expectedly, the
Raman bands of glucose are masked in the myriad signals of other
constituents and cannot be uniquely assigned by visual inspection
alone. This necessitates the use of multivariate algorithms to identify
the subtle changes and to link such changes to the glucose
concentrations at different time points.
Here, we have used the iCONIC approach to predict the glucose
concentrations with only the first reference concentration from each
subject being used to develop the model. To understand the efficacy
of the proposed method in comparison with more established
approaches, PLS calibration was also used to estimate the glucose
concentrations based on the acquired Raman spectra. Since PLS
calibration (or any other analogous implicit calibration technique
such as PCR and SVR8) method requires significantly more reference
concentrations to build a model, a cross-validation procedure is
implemented to test the predictive power of the model. While the
leave-one-out cross-validation routine (LOOCV), explained in
Methods section, avoids some of the pitfalls encountered in autop-
rediction, it may yet result in an apparently functional model (due to
‘‘overtraining’’) that cannot be used for prospective prediction23.
Nevertheless, given the problem constraints, the PLS LOOCV pro-
Figure 2 | Representative Raman spectra acquired from a human subject
undergoing OGTT. The thick line shows the mean value and the shaded
area represent 61 standard deviation.
www.nature.com/scientificreports
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cedure provides the best yardstick for comparison while also high-
lighting the need of an essentially ‘‘calibration-free’’ approach.
Fig. 3 displays the results of iCONIC prediction (red diamond)
and PLS LOOCV (black circle) in a representative subject, where the
blue squares depict the measured blood glucose values. The mea-
sured concentrations show the expected rise in glucose levels due to
ingestion of the sugar-rich drink followed by the subsequent recovery
to (nearly) euglycemic levels owing to the normal insulin response.
The recovery would be delayed or absent if a diabetic subject were
tested.We observe that the iCONICmodel (root mean squared error
of prediction, RMSEP 5 5.14 mg/dL) exhibits significantly better
prediction accuracy in comparison with the PLS LOOCV estimation
(root mean squared error of cross validation, RMSECV 5 13.64 mg/
dL). The better estimation using the iCONIC approach can be attrib-
uted to two factors, namely suitable correction for the physiological
lag between blood and ISF glucose, and the isolation of the baseline
shifts and system drifts (Supplementary Note 2). The effect of the
former can be viewed in the initial 60minutes when the glucose levels
of the subject rise sharply. During this time frame, the iCONIC
predictions match considerably better with the reference concentra-
tions, in relation to the PLS estimates, by appropriately modeling the
transient discrepancies. As noted in previous studies15,24, conven-
tional calibration methods exhibit systematic errors during rapid
excursions, even in the presence of a positive correlation between
blood and ISF glucose.
To better illustrate the predictive power when multiple human
subject data sets are included in the analysis, the results of the
iCONICmodel are plotted on theClarke error grid (Fig. 4)25, a widely
used method for quantifying the clinical usefulness of glucose pre-
dictions. Predictions in zones A and B are regarded as acceptable, and
predictions in zones C, D, and E are considered to be potentially
dangerous if used for clinical management. The RMSEP and the R2
value (coefficient of determination) are computed to be 0.54 mM
(1 mM of glucose 5 18 mg/dL) and 0.97, respectively. Critically,
all the glucose predictions over the entire human subject dataset
reside in the clinically acceptable regions – even when the glucose
levels are relatively low (4–6 mM). This result is of great value as a
key benefit of a continuous glucose monitoring system is the real-
time detection of hypoglycemic states. A common motif in diabetes
care is the lack of immediate knowledge regarding low blood glucose
excursions in over-medicated patients resulting in serious conse-
quences including diabetic coma. The ability to non-invasively and
continuously estimate blood glucose trends that is predictive of both
hypoglycemic and hyperglycemic blood glucose excursions would
address this pressing need.
Table 1 summarizes the results of the iCONIC model predictions
(viewed in Fig. 4) as well as the corresponding PLS LOOCV esti-
mates. We observe that the reduction in error on application of the
iCONIC model, when compared to the PLS model estimates, ranges
from nearly 18% to 59% with an average value of 35.5% computed
over the 8 subjects. Even when compared with our previous dynamic
concentration correction (DCC)model, which provided on average a
16% reduction in prediction error with respect to the corresponding
PLS models for the same dataset21, the iCONIC model demonstrates
much better predictive power.
Discussion
Our findings suggest that vibrational spectroscopy in combination
with the proposed iCONIC approach can provide continuous glu-
cose tracking information without necessitating substantial invasive
blood glucosemeasurements. In the following, we discuss the validity
and efficacy of this information content including the characteriza-
tion of the glucose diffusion process.
The glucose diffusion process, which was previously modeled
using a single lumped parameter13–15, is now more correctly charac-
terized using a two-parameter model (k1, k2). This ensures that the
rate of glucose uptake by the subcutaneous tissue is also addressed in
the mass diffusion process. In each of the volunteers, k1 had a larger
numerical value in relation to k2 signifying that the blood glucose rise
was faster than the return to euglycemic levels. This is consistent with
typical observations in glucose tolerance studies where the increase
in blood glucose levels following ingestion of glucose solution is rapid
in relation to the subsequent insulin-mediated glucose clearance
from the blood (by the cells) and, thus, the corresponding return
to normal blood glucose levels. One would anticipate that subjects
with impaired glucose tolerance would exhibit significant changes in
the determined rate constants, especially k2.
Critically, this allows us tomodel situations where, during the time
of decreasing glucose levels, ISF glucose may fall in advance of blood
glucose and reach nadir values that are lower than the corresponding
blood glucose levels26,27. Some studies have indicated that ISF glucose
levels can remain below blood glucose concentrations for fairly long
period of time following correction of insulin-induced hypoglyce-
Figure 3 | Plot of prospective prediction (iCONIC, red diamond),
LOOCV (PLS, black square) and reference glucose concentrations (blue
squares) for a representative human subject.
Figure 4 | Blood glucose predictions of the iCONIC model for the
complete human subject dataset shown on the Clarke Error Grid.
www.nature.com/scientificreports
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mia28. While our limited observations do not appear to support such
reports, these findings could be explicated by the so-called push-pull
phenomenon, according to which the glucose is pushed from the
blood to the ISF compartment during the rising phases and the
glucose is recruited from the ISF to the surrounding cells during
the falling phases. If this were true for a given process, our model
would re-calibrate itself by adjusting the corresponding k2 value.
Another pertinent question relates to the demonstration of caus-
ality of glucose concentration to the acquired spectral information,
especially as the intrinsic glucose signal is significantly smaller than
that of several other blood-tissue matrix constituents. Moreover,
time-dependent physiological processes or variations specific to an
instrument that happen to be correlated with the glucose levels have
often been found to dominate classical implicit calibration models,
especially for non-specific measurement modalities29. To investigate
the robustness of our predictions to chance correlations (spurious
factors), an F-test was used to compare the squared error of predic-
tion (SEP) to the standard deviation of the glucose concentrations
within the prediction data set (SDP) and, therefore, to assess if the
variability of the predicted concentrations is greater than would be
expected by chance. Here, from the values listed in Table 2, the F-
value for the PLS LOOCV estimates and the iCONIC predictions was
calculated to be 4.99 and 13.28, respectively. For the PLS computa-
tion, the SEP was replaced with SECV. Clearly, both sets of F-values
are statistically significant. Thus, the null hypothesis that the vari-
ance of errors of glucose predictions is same as the variance of the
reference glucose concentrations can be rejected. Table 2 also lists the
results for linear regression analysis of the prediction points for
the PLS and iCONIC cases. The y-intercept for the iCONIC predic-
tions is lower, the slope is closer to unity, and R2 value is higher. These
results strongly indicate that the current glucose predictions are
based on the spectroscopic properties of glucose rather than on
chance variations or correlative response between glucose and other
matrix constituents. Notably, since the iCONIC models do not use
the standard input of an array of reference concentrations, the pos-
sibility of building an apparently functional model based on incid-
ental correlations is largely eschewed.
Difference plot analysis was also performed (Supplementary Fig.
S1) for further comparison of the methods. The Bland-Altman plots
of Supplementary Fig. S1 enable the investigation of the presence of
any systematic difference between the reference and Raman mea-
surements and to identify possible outliers. Here, themean difference
is the estimated bias and is found to be 0.5 mg/dL and 24.73 mg/dL
for the PLS and iCONIC estimates, respectively. The corresponding
2SD limits are determined to be 31.9 mg/dL (PLS) and 17.1 mg/dL
(iCONIC). As per ISO 15197 guidelines, these 2SD limits should be
less than 15 mg/dL for glucose concentration below 75 mg/dL and
should be lower than 20% for any value higher than 75 mg/dL. Our
findings therefore suggest that the combination of the iCONIC
approach and Raman spectroscopy provide clinically viable predic-
tions, especially in terms of single-individual prediction.
The results presented in this manuscript provide a proof-of-con-
cept validation of the untapped potential of such a broad and widely
generalizable approach. Specific to the problem of glucose monitor-
ing, we envision that the iCONIC model can predict impending
hypo- and hyperglycemic excursions potentially allowing the dia-
betic patient to take necessary corrective action. It can also be gain-
fully employed in studying physiological changes (for example, in
micro- and macro-vasculature) due to the onset of diabetes via its
ability to characterize the glucose transport process in the circulation
system and in the ISF. A large cohort of normal human volunteers
and diabetic patients is currently being studied to test the feasibility
of this method across different ages, ethnicities and, critically, in
subjects with impaired glucose tolerance characteristics. While the
present day standard of care primarily involves interpretation of
changes in blood glucose, we believe that in specific cases measure-
ment of ISF glucose levels may be more important clinically such as
the persistence of impaired cognition for prolonged periods of time
after correction of hypoglycemia.
In the current study, we have proposed the potential of a spectro-
scopic method for tracking bioanalytes in a dynamic system with
minimal a priori concentration information. The ability of the
iCONIC approach to make accurate predictions in clinical datasets
acquired from human subjects is demonstrated in the presence of
myriad non-analyte specific variations. The performance metrics of
the iCONIC algorithm exceed that of the conventional PLS cal-
ibration method, which we attribute to its twin advantages of
accounting for the physiological lag between blood and ISF glucose,
and avoiding the baseline shifts and system drifts. While the initial
pilot studies performed here provide the foundation, further clinical
investigations - in single-center and subsequently in multi-center
settings - will be pursued to validate the approach. Furthermore,
the iCONIC formulation can be readily extended to quantify analytes
using other spectroscopic signatures such as infrared absorption and
thermal emission, which offer higher sensitivity in comparison to
Raman acquisitions30–32.
Table 1 | Summary of PLS LOOCV and iCONIC prediction results for the human subject dataset
Conventional PLS Model ICONIC Model
Subject No. of Data Points RMSECV (mM) RMSEP (mM) k1 k2 l Change in error (%)
1 25 1.17 0.68 0.0200 0.0192 0.89 42.15
2 26 0.72 0.57 0.0185 0.0178 0.77 20.39
3 26 1.28 0.53 0.0157 0.0151 0.67 58.87
4 20 0.76 0.37 0.0245 0.0240 0.36 51.31
5 32 0.56 0.46 0.0125 0.0120 0.55 17.62
6 25 0.80 0.64 0.0230 0.0217 0.38 19.47
7 26 0.83 0.44 0.0220 0.0214 0.40 46.55
8 28 0.79 0.57 0.0155 0.0148 0.25 27.84
Table 2 | Performance characteristics for the PLS and iCONIC models (* indicates SECV is the correct error metric for PLS and is used here)
Regression analysis of the prediction data
Model SDP (mg/dL) SEP (mg/dL) Model size b0 (mg/dL) b1 R2
PLS 35.57 15.92* 208 13.57 0.9057 0.9001
iCONIC 35.57 9.76 208 6.33 0.9893 0.9718
www.nature.com/scientificreports
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Given our findings and the inherent non-invasive nature of vibra-
tional spectroscopy, the combinedmethod would be appropriate as a
real-time clinical adjunct for continuous monitoring of glucose and
other blood analytes, e.g. creatinine, urea and bilirubin, in critical
care patients and in neonates, where frequent blood withdrawal is
particularly problematic. Application of this minimally perturbative
approach would also lay the foundation for a novel blood with-
drawal-free spectroscopic assay for glucose tolerance testing in the
near future. Moreover, the scope of application of this method
extends beyond in vivo diagnostics to microfluidics investigations
as well as recalcitrant industrial process monitoring, where inter-
mediate sampling of the specimen would compromise its identity.
Methods
Clinical Studies on Human Subjects. To test the capability of the iCONIC approach
in predicting concentrations from time-resolved spectra, clinical datasets comprised
of blood glucose concentrations and Raman spectra are used. These datasets, which
were detailed in one of prior reports33, were collected from healthy human volunteers
undergoing OGTT. Raman spectra were recorded at regular 5 min intervals from the
forearms of these volunteers. For Raman spectral acquisition, an 830 nm diode laser
(Process Instruments) was used as an excitation source with an average power of ca.
300 mW in a , 1 mm2 spot. On the detection end, an f/1.8 spectrograph (Kaiser
Optical Systems) was coupled to a liquid nitrogen-cooled CCD (1340 3 1300 pixels,
Roper Scientific). Bloodwas drawn every 10 min and analyzed using a clinical glucose
system (HemoCue, Inc.) to evaluate the subject’s response. This study protocol was
approved by theMITCommittee on theUse ofHumans as Experimental Subjects and
written informed consent was obtained from each of the volunteers in the study. All
the experiments were carried out in accordance with the approved guidelines by the
Committee. Data sets from volunteers exhibiting motional artifacts, inadequate SNR
in the acquired spectra, and impaired glucose tolerance characteristics are excluded
from our analysis. Additionally, two subjects who underwent double OGTTwere also
not considered in this study.
Data Analysis. To address clinical concerns arising from glucose monitoring in the
subcutaneous interstitial fluid, we have previously developed a DCC method21. This
method, which incorporates the mass transfer equations governing the diffusion of
glucose between the blood and ISF compartments into the spectroscopic framework,
provides a greater degree of consistency with the acquired spectra in the calibration
model. Here, we re-formulate the solution method to allow for subcutaneous uptake
of glucose in the ISF compartment by the cells.
Briefly, the transport of glucose from the blood to the ISF compartment occurs by a
diffusion process across an established concentration gradient19,20. As detailed in the
literature, this process can be mathematically written in the form of the following
equation for the glucose component in the ISF space:
d
dt
VISF cISFð Þ~k21 VBG cBG{ k12zk02ð Þ VISF cISF ð7Þ
where cBG, cISF are the concentrations of glucose in the blood and ISF compartments,
respectively; VBG, VISF are the volume of blood and ISF in the probed region; k21 and
k12 are the forward and reverse flux rates for glucose transport across the capillaries;
and k02 is the rate of glucose uptake into the surrounding tissue. This equation can be
re-written to the following form by reducing the additional parameters into a two-
parameter (k1, k2) system:
d
dt
cISFð Þ~k1 cBG{k2 cISF ð8Þ
Re-arranging equation (8) forms the forward iCONICmodel that is used to compute
the blood glucose concentrations based on the ISF glucose values and knowledge of
the system parameters. Additionally, integrating equation (8) provides the reverse
form of the iCONIC model, which is plugged into equation (5) that in turn performs
minimization of the objective function.
For the conventional approach, PLS models were created based on the number of
loading vectors that provide the least error in cross-validation10. The PLS models did
not explicitly address the physiological dynamics issue. Here, LOOCV approach was
used to provide concentration estimates, because of the limited number of data points
available per individual. In LOOCV, the data from a particular time point is elimi-
nated, and the PLS model developed on all the other points is used to predict the
concentration at that time point optimizing agreement with the reference measure-
ment.
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